NASDAQ
9.33USD
+0.91 (+10.81%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
507.6M
P/E
—
EPS
—
Beta
0.11
52W range
1.94-12.14
Day range
8.53–9.38
Open
8.53
Prev close
8.42
Volume
1.9M
Avg volume
1.7M
Dividend
0.00
IPO
2021-12-16
https://www.globenewswire.com/news-release/2026/08/04/3338889/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Immix-Biopharma-Inc-IMMX.html · 8/4/2026-1.00
https://www.globenewswire.com/news-release/2026/07/21/3330886/0/en/Immix-Biopharma-Investigated-by-the-Portnoy-Law-Firm.html · 7/21/2026-1.00
https://www.globenewswire.com/news-release/2026/07/20/3330141/0/en/IMMX-INVESTOR-ALERT-Holzer-Holzer-LLC-Announces-Investigation-of-Immix-Biopharma-Inc.html · 7/20/2026-1.00
https://www.zacks.com/stock/news/2939400/wall-street-analysts-think-immix-biopharma-immx-could-surge-113-58-read-this-before-placing-a-bet?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2939400 · 6/18/2026+0.80
https://www.globenewswire.com/news-release/2026/04/09/3270986/0/en/Immix-Biopharma-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html · 4/9/2026+0.90
https://www.globenewswire.com/news-release/2025/12/07/3201157/0/en/Immix-Biopharma-Announces-Pricing-of-Upsized-100-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html · 12/7/2025+0.40
https://www.globenewswire.com/news-release/2025/12/07/3201155/0/en/At-ASH-2025-Oral-Presentation-Immix-Biopharma-Reports-Positive-Phase-2-NXC-201-Results-Advancing-Toward-BLA-Submission-as-a-Potentially-First-and-Best-in-Class-Therapy-for-relapsed.html · 12/7/2025+1.00
https://www.globenewswire.com/news-release/2025/10/14/3166222/0/en/Immix-Biopharma-to-Present-at-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html · 10/14/2025+0.40
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
